News

New NHS England Cancer Strategy launched

The National Health Service (NHS) England Cancer Taskforce has recently launched a national strategy for cancer services in England, setting out the way in which the NHS can improve cancer outcomes and how patient experience of treatment and care can be improved. This latest document replaces the previous Improving outcomes: a strategy for cancer and…

Details

Publication of review on the management of spinal myeloma disease

Myeloma UK and the UK Spinal Myeloma Working Group have jointly published a paper on the optimal management of spinal disease in myeloma patients. Published in the British Journal of Haematology, the article provides an overview of the treatment and management options for spinal myeloma disease and highlights the role of defined pathways to enable the…

Details

Takeda submits ixazomib for approval as a treatment for myeloma

Takeda, the Japanese pharmaceutical company, has announced it has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) to market ixazomib as a treatment for relapsed and/or refractory myeloma patients. This is the first regulatory submission for ixazomib, an oral proteasome inhibitor, based on data from the pivotal Phase III…

Details

Orphan drug designation for novel drug CB-5083 as a treatment for myeloma

Cleave Biosciences, the US biotechnology company, has announced that its lead drug candidate CB-5083 has been granted orphan drug designation by the US Food and Drug Administration (FDA). CB-5083 is a first-in-class oral inhibitor of p97, an enzyme involved in key aspects of protein homeostasis including non-proteasomal protein degradation. Efficient removal of protein is crucial…

Details

Study shows thalidomide equally as effective as lenalidomide upfront

A study, published recently in Blood, has shown that older/less fit newly diagnosed myeloma patients treated with either melphalan, prednisolone and thalidomide (MPT-T) or melphalan, prednisolone and lenalidomide (mPR-R) had similar overall response rates, progression-free survival and overall survival. In this Phase III trial involving 306 patients with a median age of 75.7 years, median progression-free survival…

Details

Daratumumab expanded access programme initiated in the US

Janssen Biotech, Inc., which is developing daratumumab in collaboration with the Danish biotechnology company Genmab, has initiated an “expanded access programme” enabling eligible myeloma patients in the US to be treated with the drug outside of a clinical trial setting. The anti-CD38 monoclonal antibody will be available to relapsed patients who have had at least…

Details

Launch of new test to help predict prognosis of myeloma patients

SkylineDx, the Dutch-based biotechnology company which specialises in the development and commercialisation of genetic tests, has announced the launch of its MMprofiler assay, a new prognostic test for myeloma patients. Based on the measurement of the activity of 92 genes which are directly or indirectly related to myeloma, the test can be used to predict…

Details

Study shows zoledronic acid delays symptomatic progression of myeloma

A study, published recently in Haematologica, has shown that zoledronic acid does not have an anti-tumour effect in myeloma patients at asymptomatic biochemical relapse but does delay symptomatic progression and bone disease. The trial involved 100 patients at biochemical relapse who were randomly assigned to 4mg zoledronic acid every four weeks for 12 weeks or…

Details